You have full text access to this Open Access content

Cancer Science

Cover image for Vol. 105 Issue 1

January 2014

Volume 105, Issue 1

Pages January cover–January cover, i–iii, 1–141

  1. COVER IMAGE

    1. Top of page
    2. COVER IMAGE
    3. ISSUE INFORMATION
    4. IN THIS ISSUE
    5. REVIEW ARTICLE
    6. ORIGINAL ARTICLES
    7. Retraction
    1. You have full text access to this Open Access content
      Nardilysin protein promotes invasion of esophageal cell carcinoma (ESCC) cells through induction of MMP2 and MMP3. Immunohistochemical analysis of nardilysin in ESCC tissue (page January cover)

      Naohiro Uraoka, Naohide Oue, Naoya Sakamoto, Kazuhiro Sentani, Htoo Zarni Oo, Yutaka Naito, Tsuyoshi Noguchi and Wataru Yasui

      Article first published online: 24 JAN 2014 | DOI: 10.1111/cas.12325

  2. ISSUE INFORMATION

    1. Top of page
    2. COVER IMAGE
    3. ISSUE INFORMATION
    4. IN THIS ISSUE
    5. REVIEW ARTICLE
    6. ORIGINAL ARTICLES
    7. Retraction
    1. You have full text access to this Open Access content
      Issue Information (pages i–ii)

      Article first published online: 24 JAN 2014 | DOI: 10.1111/cas.12254

  3. IN THIS ISSUE

    1. Top of page
    2. COVER IMAGE
    3. ISSUE INFORMATION
    4. IN THIS ISSUE
    5. REVIEW ARTICLE
    6. ORIGINAL ARTICLES
    7. Retraction
    1. You have full text access to this Open Access content
  4. REVIEW ARTICLE

    1. Top of page
    2. COVER IMAGE
    3. ISSUE INFORMATION
    4. IN THIS ISSUE
    5. REVIEW ARTICLE
    6. ORIGINAL ARTICLES
    7. Retraction
    1. You have full text access to this OnlineOpen article
      Clinical significance of macrophage heterogeneity in human malignant tumors (pages 1–8)

      Yoshihiro Komohara, Masahisa Jinushi and Motohiro Takeya

      Article first published online: 29 NOV 2013 | DOI: 10.1111/cas.12314

      Thumbnail image of graphical abstract

      Heterogeneity of TAM differentiation is now focused, and M2 TAM is contributed to tumor progression in human cancers. We review recent studies which investigated TAMs in human cancers.

  5. ORIGINAL ARTICLES

    1. Top of page
    2. COVER IMAGE
    3. ISSUE INFORMATION
    4. IN THIS ISSUE
    5. REVIEW ARTICLE
    6. ORIGINAL ARTICLES
    7. Retraction
    1. BASIC AND CLINICAL IMMUNOLOGY

      You have full text access to this OnlineOpen article
      In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies (pages 9–17)

      Xu-Dong Tang, Shu-Liang Guo, Guo-Zhen Wang, Ning Li, Yu-Yun Wu, Dian-Chun Fang, Ya-Han Fan and Shi-Ming Yang

      Article first published online: 29 NOV 2013 | DOI: 10.1111/cas.12308

      Thumbnail image of graphical abstract

      Cytotoxic T lymphocytes induced by epitopes from heparanase could lyse various cancer cells in vitro and ex vivo.

    2. CARCINOGENESIS

      You have full text access to this OnlineOpen article
      Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2 (pages 18–25)

      Xiaojian Ni, Tiansong Xia, Yingchun Zhao, Wenbin Zhou, Naping Wu, Xiaoan Liu, Qiang Ding, Xiaoming Zha, Jiahao Sha and Shui Wang

      Article first published online: 4 DEC 2013 | DOI: 10.1111/cas.12309

      Thumbnail image of graphical abstract

      MMP2 upregulation plays an important role in BC bone metastasis through ERK pathways, and miR-106b directly regulates MMP2 expression. The miR-106b/MMP2/ERK pathway may be a promising therapeutic target for inhibiting BC bone metastasis.

    3. CELL, MOLECULAR, AND STEM CELL BIOLOGY

      You have full text access to this OnlineOpen article
      CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer (pages 26–34)

      Yu Su, Yi Lin, Lianhai Zhang, Baocai Liu, Wanqiong Yuan, Xiaoning Mo, Xiaohong Wang, Henan Li, Xiaofang Xing, Xiaojing Cheng, Bin Dong, Ying Hu, Hong Du, Yubing Zhu, Ning Ding, Jiyou Li, Weili Liu, Yongzhen Ma, Xiaoyan Qiu, Jiafu Ji and Wenling Han

      Article first published online: 28 NOV 2013 | DOI: 10.1111/cas.12304

      Thumbnail image of graphical abstract

      CMTM3, a novel tumor suppressor gene, was silenced in several gastric cancer cell lines and dramatically downregulated in gastric cancer tissues. CMTM3 inhibited the migration and invasion of gastric cancer cells both in vitro and in vivo, and reduced MMP2 expression and ERK1/2 phosphorylation. More importantly, CMTM3 was associated with favourable prognosis in gastric cancer.

    4. You have full text access to this OnlineOpen article
      De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity (pages 35–43)

      Takashi Tokunaga, Akihiro Tomita, Keiki Sugimoto, Kazuyuki Shimada, Chisako Iriyama, Tatsuya Hirose, Mizuho Shirahata-Adachi, Yasuhiro Suzuki, Hiroki Mizuno, Hitoshi Kiyoi, Naoko Asano, Shigeo Nakamura, Tomohiro Kinoshita and Tomoki Naoe

      Article first published online: 22 DEC 2013 | DOI: 10.1111/cas.12307

      Thumbnail image of graphical abstract

      Some de novo DLBCL show CD20 IHC(+)/FCM(−) phenotype. Lower CD20 mRNA expression is closely related to this phenomenon. Since partial effectiveness of rituximab was confirmed in CDC assay in vitro, rituximab utilization for those patients may be still recommended.

    5. You have full text access to this OnlineOpen article
      Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model (pages 44–51)

      Jingjia Ye, Makiko Kawaguchi, Yukihiro Haruyama, Ai Kanemaru, Tsuyoshi Fukushima, Koji Yamamoto, Chen-Yong Lin and Hiroaki Kataoka

      Article first published online: 25 NOV 2013 | DOI: 10.1111/cas.12306

      Thumbnail image of graphical abstract

      HAI-1 suppresses invasion and metastasis of human pancreatic cancer cells.

    6. You have full text access to this OnlineOpen article
      Ganglioside GD3 induces convergence and synergism of adhesion and hepatocyte growth factor/Met signals in melanomas (pages 52–63)

      Keiko Furukawa, Mariko Kambe, Maiko Miyata, Yuki Ohkawa, Orie Tajima and Koichi Furukawa

      Article first published online: 22 DEC 2013 | DOI: 10.1111/cas.12310

      Thumbnail image of graphical abstract

      Ganglioside GD3 has been considered to be a melanoma-associated glycolipid antigen. Here, we demonstrated that GD3 plays a crucial role in the convergence of multiple signals, leading to the synergistic effects of those signals on malignant properties of melanomas.

    7. You have full text access to this OnlineOpen article
      Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3 (pages 64–71)

      Xiangrong Cui, Jianping Liu, Lu Bai, Jie Tian and Jing Zhu

      Article first published online: 30 DEC 2013 | DOI: 10.1111/cas.12313

      Thumbnail image of graphical abstract

      In this work, we demonstrated that over expression of IL-6 could promote MSCs malignat transformation in the tumor microenvironment and the malignant transformed MSCs could form tumors afer implanted in nude mice, and suggests that IL-6 released from the cancer cells have a critical role in the malignant transformation of MSCs.

    8. You have full text access to this OnlineOpen article
      Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells (pages 72–80)

      Takayuki Uehara, Takeharu Kanazawa, Hiroaki Mizukami, Ryosuke Uchibori, Tomonori Tsukahara, Masashi Urabe, Akihiro Kume, Kiyoshi Misawa, Thomas E. Carey, Mikio Suzuki, Keiichi Ichimura and Keiya Ozawa

      Article first published online: 1 DEC 2013 | DOI: 10.1111/cas.12315

      Thumbnail image of graphical abstract

      Transduced HEp-2 and KB cell lines using a recombinant adeno-associated virus (rAAV)-GFP vector showed a high GFP expression rate. GALR2 express in the presence of galanin suppressed cell viability in both cell lines. The annexin V-positive rate and sub-G0/G1 phase population were significantly elevated in the both cells. Furthermore, in HEp-2 cells, GALR2-mediated apoptosis was caspase-independent, involving down-regulation of ERK1/2, followed by induction of the pro-apoptotic Bcl-2 protein, Bim.

    9. CLINICAL RESEARCH

      You have full text access to this OnlineOpen article
      p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors (pages 81–88)

      Mitsugu Yamamoto, Mitsuchika Hosoda, Kiichiroh Nakano, Shusheng Jia, Kanako C. Hatanaka, Emi Takakuwa, Yutaka Hatanaka, Yoshihiro Matsuno and Hiroko Yamashita

      Article first published online: 22 NOV 2013 | DOI: 10.1111/cas.12302

      Thumbnail image of graphical abstract

      Expression of p53, as well as expression of ER, PgR, HER2 and Ki67 by immunohistochemistry were investigated in postmenopausal ER-positive breast cancer patients who were treated with aromatase inhibitors as adjuvant endocrine therapy. Our study demonstrates that p53 accumulation is a strong predictor of both early and late recurrence.

    10. You have full text access to this OnlineOpen article
      Polymorphisms of EpCAM gene and prognosis for non-small-cell lung cancer in Han Chinese (pages 89–96)

      Yuefan Yang, Fei Fei, Yang Song, Xiaofei Li, Zhipei Zhang, Zhou Fei, Haichuan Su and Shaogui Wan

      Article first published online: 4 DEC 2013 | DOI: 10.1111/cas.12318

      Thumbnail image of graphical abstract

      This study reported the associations between a non-synonymous SNP rs1126497 in EpCAM gene and clinical outcomes in non-small cell lung cancer patients, which implicated the clinical significance of genetic variations as potential prognostic biomarker for lung cancer patients.

    11. You have full text access to this OnlineOpen article
      Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts (pages 97–104)

      Takaaki Ono, Akihiro Takeshita, Yuji Kishimoto, Hitoshi Kiyoi, Masaya Okada, Takahiro Yamauchi, Nobuhiko Emi, Kentaro Horikawa, Mitsuhiro Matsuda, Katsuji Shinagawa, Fumihiko Monma, Shigeki Ohtake, Chiaki Nakaseko, Masatomo Takahashi, Yukihiko Kimura, Masako Iwanaga, Norio Asou, Tomoki Naoe and for The Japan Adult Leukemia Study Group

      Article first published online: 9 JAN 2014 | DOI: 10.1111/cas.12319

      Thumbnail image of graphical abstract

      We assessed clinical significance of CD56 antigen in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy. Our study showed a significant correlation of CD56 expression with lower platelet counts and severe disseminated intravascular coagulation. Among patients with initial white blood cell counts of 3.0 × 109/L or more, event-free survival (EFS) and cumulative incidence of relapse in CD56+ APL were significantly worse, and in multivariate analysis, CD56 expression was an unfavorable prognostic factor for EFS.

    12. You have full text access to this OnlineOpen article
      European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients (pages 105–109)

      Eri Yamamoto, Shin Fujisawa, Maki Hagihara, Masatsugu Tanaka, Katsumichi Fujimaki, Kumiko Kishimoto, Chizuko Hashimoto, Megumi Itabashi, Daisuke Ishibashi, Yuki Nakajima, Takayoshi Tachibana, Rika Kawasaki, Hideyuki Kuwabara, Hideyuki Koharazawa, Etsuko Yamazaki, Naoto Tomita, Rika Sakai, Hiroyuki Fujita, Heiwa Kanamori and Yoshiaki Ishigatsubo

      Article first published online: 23 JAN 2014 | DOI: 10.1111/cas.12321

      Thumbnail image of graphical abstract

      The EUTOS score did not predict the outcome of the newly diagnosed CML-CP patients treated with imatinib. However, there were significant differences in both the Sokal score and Hasford score risk groups.

    13. DRUG DISCOVERY AND DELIVERY

      You have full text access to this OnlineOpen article
      High antitumor activity of pladienolide B and its derivative in gastric cancer (pages 110–116)

      Momoko Sato, Naoki Muguruma, Tadahiko Nakagawa, Koichi Okamoto, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Katsutaka Sannomiya, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Hiroaki Mikasa, Satoshi Wada, Masao Iwata and Tetsuji Takayama

      Article first published online: 4 DEC 2013 | DOI: 10.1111/cas.12317

      Thumbnail image of graphical abstract

      The pladienolide B and its derivative showed very high anti-tumor activity against various gastric cancer cell lines and primary cultured gastric cancer cells from carcinomatous ascites in vitro and in a xenograft model. The mechanism of the anti-tumor activity of pladienolide B involves splicing impairment and apoptosis induction.

    14. You have full text access to this OnlineOpen article
      Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants (pages 117–125)

      Jie Zhao, Haitian Quan, Yongping Xu, Xiangqian Kong, Lu Jin and Liguang Lou

      Article first published online: 4 JAN 2014 | DOI: 10.1111/cas.12320

      Thumbnail image of graphical abstract

      Acquired drug resistance due to secondary mutations does occur and forms a major problem for targeted therapies. Here, we found that flumatinib, a selective KIT inhibitor, effectively overcame imatinib- and sunitinib-resistance of certain KIT mutants with secondary mutations in the activation loop. Our findings suggest that flumatinib may be a promising therapeutic agent for patients with KIT–positive malignancies which fail to respond to imatinib or sunitinib treatment.

    15. PATHOLOGY

      You have full text access to this OnlineOpen article
      Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach (pages 126–133)

      Kazuo Shiratsu, Kayoko Higuchi and Jun Nakayama

      Article first published online: 22 NOV 2013 | DOI: 10.1111/cas.12305

      Thumbnail image of graphical abstract

      Loss of αGlcNAc in MUC6-positive cancer cells is associated with progression and poor prognosis in differentiated but not undifferentiated types of gastric adenocarcinoma.

    16. You have full text access to this OnlineOpen article
      NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression (pages 134–140)

      Naohiro Uraoka, Naohide Oue, Naoya Sakamoto, Kazuhiro Sentani, Htoo Zarni Oo, Yutaka Naito, Tsuyoshi Noguchi and Wataru Yasui

      Article first published online: 29 NOV 2013 | DOI: 10.1111/cas.12316

      Thumbnail image of graphical abstract

      Univariate and multivariate analyses revealed that nardilysin expression is an independent prognostic classifier of patients with esophageal squamous cell carcinoma. The invasiveness of NRD1-knockdown TE1 and TE5 esophageal cancer cell lines was less than that of the negative control siRNA-transfected cell lines. These results suggest that nardilysin is involved in tumor progression, and is an independent prognostic classifier in patients with esophageal squamous cell carcinoma.

  6. Retraction

    1. Top of page
    2. COVER IMAGE
    3. ISSUE INFORMATION
    4. IN THIS ISSUE
    5. REVIEW ARTICLE
    6. ORIGINAL ARTICLES
    7. Retraction
    1. You have full text access to this Open Access content

SEARCH

SEARCH BY CITATION